Clinical Trials Logo

Other clinical trials

View clinical trials related to Other.

Filter by:

NCT ID: NCT04347967 Not yet recruiting - Clinical trials for Acute Respiratory Distress Syndrome

Mesenchymal Stem Cells for The Treatment of Acute Respiratory Distress Syndrome (ARDS)

Start date: January 1, 2024
Phase: Phase 1
Study type: Interventional

The clinical study with UMC119-06 is designed to investigate the safety in patients with moderate acute respiratory distress syndrome ("ARDS"). This will be a dose escalation, open-label, single-center study in adult with ARDS. UMC119-06 is ex vivo cultured human umbilical cord derived mensenchymal stem cells (hUC-MSCs) product which is intended for treatment of ARDS.

NCT ID: NCT04346069 Not yet recruiting - Clinical trials for Disorder of Speech and Language Development

Role Of Parent-Child Interaction Therapy Towards Management Of Language And Behavioral Problems Among Children

Start date: June 2020
Phase: N/A
Study type: Interventional

maltreatment are particularly vulnerable towards child abuse and developing mental and physical health issues. parent child interaction therapy (PCIT)) is one of those interventions which can address these vulnerabilities by improving parent to child relation and interaction, primarily improving parenting skills and helping parents cope with their parenting stress and child's behavioral problems. PCIT is empirically validated to decrease parenting stress, couple conflict and enhance parent child interaction, resulting in better coping skills while parenting for a child with disability. This research is very vital as it measures the efficacy of parent child interaction. In Pakistan mostly parents are bringing their children to clinic without any support from government therefore it is not possible for everyone to get daily based therapeutic intervention. The area of Parent-child Interaction Therapy and the acceptance of these treatments are new and emerging in Pakistani Health Care, apart from above; this research will also assist in identifying further areas of research.

NCT ID: NCT04345588 Not yet recruiting - Clinical trials for Dexamethasone Efficacy as an Adjuvant in Supraclavicular Block

Dexamethasone as an Adjuvant in Supraclavicular Block

Start date: January 1, 2021
Phase: Phase 2
Study type: Interventional

The use of dexamethasone perineurally along with local anesthetic has been shown to improve the duration of analgesia .

NCT ID: NCT04344158 Not yet recruiting - Clinical trials for Advanced Hepatocellular Carcinoma (HCC)

A Phase III Clinical Trial of AK105 Injection Combined With Anlotinib Hydrochloride Capsules Versus Sorafenib in Subjects With Advanced Hepatocellular Carcinoma (HCC)

Start date: May 1, 2020
Phase: Phase 3
Study type: Interventional

This is a randomized, controlled, open-label, multicenter study to evaluate efficacy of AK105 injection combined with Anlotinib Hydrochloride Capsules versus Sorafenib. Patients are treated with AK105 injection combined with Anlotinib Hydrochloride Capsules or Sorafenib, with 2:1 random ratio. Every 21 days is a treatment cycle.

NCT ID: NCT04343846 Not yet recruiting - Clinical trials for Eruption Statues of Primary Teeth in LBW Children

Eruption Status of Primary Teeth in Low Birth Weight Children in Comparison to Normal Birth Weight Childern

Start date: August 1, 2020
Phase:
Study type: Observational

determine the status of eruption of primary teeth and physical growth in children aged from 6 to 36 months with low birth weight in comparison to normal birth weight

NCT ID: NCT04342013 Not yet recruiting - Clinical trials for Perioperative Medication Errors

RCT: The Effect of an Electronic Clinical Decision Support Application on Perioperative Medication Errors.

Start date: March 2021
Phase: N/A
Study type: Interventional

The purpose of this study is to assess the effect of a novel clinical decision support application on the rate of perioperative medication errors and preventable adverse medication events. The investigators hypothesize that the perioperative clinical decision support application will reduce the incidence of perioperative medication errors and adverse medication events compared to the standard of care.

NCT ID: NCT04341077 Not yet recruiting - Clinical trials for Healthy Adult Male and Female Volunteers

Study to Evaluate the Safety and Pharmacokinetics of Single-Dose Fluzoparib in Healthy Chinese Subjects

Start date: April 10, 2020
Phase: Phase 1
Study type: Interventional

Study to Evaluate the Safety and Pharmacokinetics of Single-Dose Fluzoparib in Healthy Chinese Subjects

NCT ID: NCT04341051 Not yet recruiting - Clinical trials for Peripheral Artery Occlusive Disease

Sciatic Block Increases Regional Saturation in Peripheral Artery Occlusive Disease.

Start date: April 1, 2020
Phase:
Study type: Observational [Patient Registry]

We conducted Single-center prospective observational study to evaluate the improvement of peripheral vascular perfusion monitored with near-infrared spectroscopy, in patients undergoing endovascular surgery after performing sciatic nervous block.

NCT ID: NCT04339829 Not yet recruiting - Clinical trials for Dacomitinib for EGFR Mutated Non-Small Cell Lung Cancer (NSCLC) With Brain Metastases

An Open Label, Multicenter, Phase II Study of Dacomitinib for EGFR Mutated Non-Small Cell Lung Cancer (NSCLC) With Brain Metastases

Start date: August 1, 2020
Phase: Phase 2
Study type: Interventional

This is a multi-center, single-arm, open-label, Phase 2 clinical study of Dacomitinib for EGFR Mutated Non-Small Cell Lung Cancer (NSCLC) With Brain Metastases.

NCT ID: NCT04338282 Not yet recruiting - Clinical trials for Extranodal NK/T-cell Lymphoma, Nasal Type

Maintenance Therapy With Anti-PD-1 Antibody for Patients With NK/T-cell Lymphoma

Start date: June 1, 2020
Phase: Phase 2
Study type: Interventional

For patients with NK/T-cell lymphoma, plasma EBV-DNA has been found to be a prognostic factor, and those with positive plasma EBV-DNA at the end of treatments are more likely to suffer from disease relapse. Thus, this study aims to evaluate the role of maintenance with anti-PD-1 antibody.